Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC-HF: Ferric Derisomaltose in Chronic Heart Failure with Iron Deficiency
NCT06929806Phase 3Recruiting
- Sponsor
- Pharmacosmos
- Start
- May 2025
- Primary completion
- Dec 2027
- Modality
- Inorganic Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of ferric derisomaltose in chronic heart failure (CHF) and iron deficiency anemia (IDA) (2 arms), sponsored by Pharmacosmos. Primary endpoint: Number of cardiovascular deaths and hospitalizations for worsening heart failure at 52 weeks. Started May 2025; status: recruiting.
02
Drugs
ferric derisomaltose
03
Conditions
chronic heart failure (CHF)iron deficiency anemia (IDA)
Beyond the preview
Go deeper on NCT06929806.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929806.